Europe's AgTech Leader Is Losing Its Edge—Here's Why

Jan de Vries · 2026-10-30

The Netherlands has long been the quiet overachiever of European agriculture. Tiny country, massive output. But a new report from Invest-NL, the Dutch national investment institution, suggests that crown is starting to slip. And the reasons why should matter to anyone watching European startup incorporation. The report, called *Deep Dive Agrifood Biotech*, drops a number that's hard to ignore: solving the bottlenecks facing Dutch agrifood biotech companies could unlock about $18.5 billion in extra annual revenue by 2040. That's not pocket change. But without coordinated action on regulation, financing, and commercialization, most of that upside will land somewhere else. So what's actually going wrong? Let's break it down. ### A strong start, a weak finish The Netherlands has world-class research institutions, established seed breeders, and a food production ecosystem that most countries would kill for. On paper, it's a powerhouse. In practice, scientific excellence isn't translating into globally competitive businesses. Here's the telling stat: the Netherlands accounts for 3.3% of BioTech startups worldwide, but only 1.3% of scale-ups. That gap is the whole story. The country is great at generating innovation and less great at helping young companies grow into something meaningful. Invest-NL points to three recurring weaknesses: - Too few promising technologies become scalable ventures - Regulatory and validation processes delay market entry - Insufficient financing prevents companies from reaching industrial production The stakes go beyond individual businesses. In a favorable scenario, annual Dutch agrifood BioTech revenues could hit roughly $27 billion by 2040. Under current conditions? Just $8.7–9.8 billion. That's a massive difference. ### Ten years to say yes One of the most frustrating obstacles involves biological crop protection—the alternatives to conventional chemical pesticides that Dutch companies are developing. Getting European regulatory approval for a new biological crop protection product can take eight to ten years. Existing frameworks were designed around chemicals, so they fit biological innovations poorly. As a result, some companies launch in Brazil and the United States first, where commercialization moves faster. Invest-NL warns that Europe risks losing ground in a market that could expand seven- to tenfold by 2040. Food biotechnology faces similar headaches. Regulatory approval for novel ingredients takes one to three years longer in Europe than in the U.S., and building a first commercial production facility can require tens or even hundreds of millions of dollars. For fermentation-derived food ingredients alone, favorable conditions could support about $8.7 billion in annual Dutch revenues by 2040. Under existing policies, it's closer to $2.2 billion. The report is careful to say faster approvals shouldn't come at the expense of safety. Instead, regulators should offer earlier guidance, more predictable assessments, and chances for companies to validate products in real-world conditions. > "Innovation is not the issue," the report notes. "Commercialization is." ### What this means for founders and investors If you're building in agrifood biotech or thinking about where to incorporate in Europe, this report is a warning shot. The Netherlands still has the talent, the research, and the infrastructure. But the gap between startup and scale-up is where fortunes get lost. For now, the smart play might be to keep IP and strategic capabilities in Europe while using production networks elsewhere. But that's a holding pattern, not a strategy. Unless regulation and financing catch up, the next big agrifood breakthrough might not be Dutch at all.